Abstract |
Targeted delivery of IL-12 might turn this cytokine into a safer, more effective cancer therapeutic. Here we describe a novel immunocytokine, NHS-IL12, consisting of two molecules of IL-12 fused to a tumor necrosis-targeting human IgG1 (NHS76). The addition of the human IgG1 moiety resulted in a longer plasma half-life of NHS-IL12 than recombinant IL-12, and a selective targeting to murine tumors in vivo. Data from both in vitro assays using human PBMCs and in vivo primate studies showed that IFN-gamma production by immune cells is attenuated following treatment with the immunocytokine, suggesting an improved toxicity profile than seen with recombinant IL-12 alone. NHS-IL12 was superior to recombinant IL-12 when evaluated as an anti- tumor agent in three murine tumor models. Mechanistic studies utilizing immune cell subset-depleting antibodies, flow cytometric methods, and in vitro cytotoxicity and ELISA assays all indicated that the anti- tumor effects of NHS-IL12 were primarily CD8+ T cell-dependent and likely IL-12-mediated. Combining NHS-IL12 treatment with a cancer vaccine, radiation, or chemotherapy resulted in greater anti- tumor effects than each individual therapy alone. These preclinical findings provide a rationale for the clinical testing of this immunocytokine, both as a single agent and in combination with vaccines, radiation and chemotherapy.
|
Authors | Jonathan Fallon, Robert Tighe, Giorgio Kradjian, Wilson Guzman, Anna Bernhardt, Berend Neuteboom, Yan Lan, Helen Sabzevari, Jeffrey Schlom, John W Greiner |
Journal | Oncotarget
(Oncotarget)
Vol. 5
Issue 7
Pg. 1869-84
(Apr 15 2014)
ISSN: 1949-2553 [Electronic] United States |
PMID | 24681847
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cancer Vaccines
- Immunoglobulin G
- Indoles
- L-BLP25
- Membrane Glycoproteins
- NHS-IL12 immunocytokine
- Pyrroles
- Recombinant Fusion Proteins
- Taxoids
- Docetaxel
- Interleukin-12
- Interferon-gamma
- Sunitinib
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(immunology, pharmacology, therapeutic use)
- CD8-Positive T-Lymphocytes
- Cancer Vaccines
(administration & dosage, therapeutic use)
- Cell Line, Tumor
- Docetaxel
- Female
- Humans
- Immunoglobulin G
(immunology, pharmacology, therapeutic use)
- Immunomodulation
- Indoles
(administration & dosage)
- Interferon-gamma
(metabolism)
- Interleukin-12
(immunology, pharmacology, therapeutic use)
- Lymphocyte Activation
(drug effects)
- Macaca fascicularis
- Membrane Glycoproteins
(therapeutic use)
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Neoplasms, Experimental
(therapy)
- Protein Engineering
- Pyrroles
(administration & dosage)
- Recombinant Fusion Proteins
(immunology, pharmacology, therapeutic use)
- Sunitinib
- Survival Rate
- Taxoids
(administration & dosage)
- Tumor Burden
|